PMID- 7799012
OWN - NLM
STAT- MEDLINE
DCOM- 19950123
LR  - 20170210
IS  - 0732-183X (Print)
IS  - 0732-183X (Linking)
VI  - 13
IP  - 1
DP  - 1995 Jan
TI  - Results of the United Kingdom Children's Cancer Study Group first Wilms' Tumor 
      Study.
PG  - 124-33
AB  - PURPOSE: The first United Kingdom Children's Cancer Study Group (UKCCSG) Wilms' 
      Tumor Trial (UKW1) applied treatment regimens stratified by stage and histology 
      in accordance with National Wilms' Tumor Study (NWTS) criteria, seeking to reduce 
      treatment of low-stage, favorable-histology (FH) tumors without impairing 
      survival and to improve prognosis of stage III and IV (FH) and 
      unfavorable-histology (UH) tumors with more intensive chemotherapy. PATIENTS AND 
      METHODS: Three hundred eighty-four consecutively diagnosed patients with Wilms' 
      tumor were recruited from the 20 UKCCSG centers and Oslo, Norway, between January 
      1980 and June 1986. The regimen for stage I patients was vincristine (Vcr) only, 
      while stage II patients received Vcr and dactinomycin (Act-D). Stage III patients 
      received three-drug therapy and stage IV and UH patients four-drug regimens. 
      Act-D was given as pulsed doses of 1.5 mg/m2 every 3 or every 6 weeks. No lung 
      irradiation was used in stage IV patients. No randomized comparisons were 
      attempted. End points were survival and event-free survival (EFS). RESULTS: 
      Survival at 6 years in FH patients was 96% for stage I, 93% for stage II, 83% for 
      stage III, 65% for stage IV, and 50% for UH patients of all stages. CONCLUSION: 
      Vcr alone is as effective for stage I FH tumors as the two-drug regimen used in 
      the NWTS and International Society of Pediatric Oncology (SIOP) studies. 
      Fractionation of Act-D is unnecessary. The poorer results for stage IV FH and UH 
      patients compared with the NWTS may be due to treatment differences, such as the 
      use of lung irradiation for stage IV FH patients in NWTS3, and/or to case 
      selection bias.
FAU - Pritchard, J
AU  - Pritchard J
AD  - Department of Epidemiology and Public Health, University of Leicester, United 
      Kingdom.
FAU - Imeson, J
AU  - Imeson J
FAU - Barnes, J
AU  - Barnes J
FAU - Cotterill, S
AU  - Cotterill S
FAU - Gough, D
AU  - Gough D
FAU - Marsden, H B
AU  - Marsden HB
FAU - Morris-Jones, P
AU  - Morris-Jones P
FAU - Pearson, D
AU  - Pearson D
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of 
      Clinical Oncology
JID - 8309333
RN  - 1CC1JFE158 (Dactinomycin)
RN  - 5J49Q6B70F (Vincristine)
SB  - IM
CIN - J Clin Oncol. 1995 Jun;13(6):1530. PMID: 7751904
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use
MH  - Chemotherapy, Adjuvant
MH  - Child
MH  - Child, Preschool
MH  - Dactinomycin/administration & dosage
MH  - Humans
MH  - Infant
MH  - Kidney Neoplasms/*drug therapy/mortality/pathology/radiotherapy/surgery
MH  - Neoplasm Staging
MH  - United Kingdom
MH  - Vincristine/administration & dosage
MH  - Wilms Tumor/*drug therapy/mortality/pathology/radiotherapy/surgery
EDAT- 1995/01/01 00:00
MHDA- 1995/01/01 00:01
CRDT- 1995/01/01 00:00
PHST- 1995/01/01 00:00 [pubmed]
PHST- 1995/01/01 00:01 [medline]
PHST- 1995/01/01 00:00 [entrez]
AID - 10.1200/JCO.1995.13.1.124 [doi]
PST - ppublish
SO  - J Clin Oncol. 1995 Jan;13(1):124-33. doi: 10.1200/JCO.1995.13.1.124.